For example, MG1 (immunogenic) meningiomas from our study logically corresponds to the IE group from Choudhury et al., and MenG B from Bayley et al.; these groups are largely comprised of NF2-altered, benign meningiomas enriched for pathways involved in immune signalling and immune cell infiltration of the tumor microenvironment. The gene discussed is MUC5B; the disease is meningioma.